A Pfizer result is unsettling the gene therapy push for Duchenne muscular dystrophy: The boys didn't improve even though a ...

A Phase 3 clinical trial investigating Elevidys (delandistrogene moxeparvovec), a gene therapy for Duchenne muscular ...

SAVANNAH, Ga. -- Delandistrogene moxeparvovec (Elevidys), a gene therapy approved to treat Duchenne muscular dystrophy, ...

Pfizer has told 75 employees in Sanford, North Carolina, that their positions have been eliminated. | Pfizer has told 75 ...

We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a ...

Two Chinese biotechs are testing CRISPR gene editing in boys with muscular dystrophy, even as projects at U.S. companies like ...

The full results from Pfizer’s pivotal study of its Duchenne muscular dystrophy gene therapy show patients saw no significant ...

Because sickle cell disease isn’t as progressive a disease as others that have gene therapies available, there isn’t as much ...

Sidra Medicine s Genetic and Genomic Medicine clinic is providing life altering gene therapy for rare genetic disorders. In a ...

Capricor Therapeutics is taking a victory lap for their phase 2 Duchenne muscular dystrophy (DMD) trial. | Capricor ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Wave Life Sciences (NASDAQ:WVE) is developing a treatment for Duchenne Muscular Dystrophy ... in exon 53 of the dystrophin gene. It is a type of gene therapy that aims to restore the production ...